Denmark's Lundbeck has signed an agreement with information business Elsevier, that aims to help organise the masses of scientific data it has available, and make drug research more product
Danish drugmaker Lundbeck saw more than a quarter of the value wiped off its shares yesterday after its top pipeline prospect, a drug for schizophrenia, missed the mark in a phase III trial.
Denmark’s Lundbeck is bringing a third potential drug for Parkinson’s disease to the clinic – a human antibody that the company hopes will tackle the underlying cause of the condition.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.